• Annals of the Rheumatic Diseases publishes results from two bimekizumab Phase 3 studies in axial spondyloarthritis

    Wednesday January 18th 2023

  • Oxurion announces the continuation of KALAHARI Phase 2, Part B Study in diabetic macular edema following interim analysis

    Friday December 16th 2022

  • UCB announces positive Phase 3 studies for bimekizumab in hidradenitis suppurativa

    Friday December 9th 2022

  • Oxurion: Interim analysis for KALAHARI trial planned by year-end 2022 with full top-line data expected in second half of 2023

    Monday November 21st 2022

  • Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia

    Tuesday November 15th 2022

  • Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON

    Tuesday November 15th 2022

  • Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)

    Tuesday October 25th 2022

  • Mithra announces positive preclinical data demonstrating Estetrol’s efficacy in wound healing

    Wednesday October 12th 2022

  • Your news here?

  • Indigo Diabetes announces first participant enrolled in the SHINE clinical trial

    Thursday September 29th 2022

  • reMYND identifies novel target and small molecules with potential to halt and reverse disease progression in Huntington’s disease through oral administration

    Wednesday August 31st 2022

  • Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial

    Monday August 1st 2022


Strategic Partners